NW Bio announced presentation at ASCO of preliminary testing DCVax-L

The company is Northwest Biotherapeutics (code OTCQB: NWBO) (NW Bio) is a biotechnology company specializing in the development of personalized immune therapy DCVax® for dense tumors, reported that on Sunday, 3 June, at 16:15 Central time, in the sector Industry Expert Theater showroom of ASCO conference, which will be held on site at Mc Cormick Place Convention Center in Chicago, technical Director of NW Bio Dr. Marnix Bosch (Marnix L. Bosch) discuss with industry experts published may 29 interim results of the 3rd phase of clinical trials of the effectiveness of DCVax®-L in the treatment of newly diagnosed glioblastoma of the brain.

In addition, if time allows, specially invited doctors and patients, overcoming his disease, talk about your experience with DCVax-L.

The company plans to organize a webcast of the presentation, Dr. Bosch. Detailed information will be published on the website of the Company in the "Recent presentations". It is anticipated that the webcast will be available for repeat viewing after the presentation on the website of the company. The planned event is not an official presentation in the framework of the Annual meeting of ASCO-2018. It's not sponsored, supported or accredited by ASCO or Conquer Cancer Foundation Fund. Not CME accredited.